A Phase 3 interventional study of Transdermal 17Beta-estradiol, progesterone and Ethinyl Estradiol + Desogestrel in Exercise-related Amenorrhea, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 14 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.
Among the 43 studies in Amenorrhea with a site in United States, this one is the 8th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 in phase 3, and was the 17th registered.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
Browse Amenorrhea studies →7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
University of Virginia · Sites in United States
Ages 14–30 · Women only
Massachusetts General Hospital · Sites in United States
Ages 14–30 · Women only
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
University of Colorado, Colorado Springs · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.
This study: 14 Years to 21 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 1989; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.
Median enrollment 37 across the 30 interventional studies, 111 across the 13 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 8 studies filed under Amenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Amenorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00589654Memorial Sloan Kettering Cancer CenterMenstrual Cycle Maintenance and Quality of Life: A Prospective Study | 2026-12 |
| NCT05629377Mayo ClinicHypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH) | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Amenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes. The second aim of this study is to determine whether transdermal or oral estrogen (versus no estrogen) is effective in increasing bone density and improving bone microarchitecture in adolescent athletes who are not getting their periods and are thus estrogen deficient. The investigators hypothesize that transdermal estrogen will be more effective than oral estrogen or no estrogen in improving bone health in amenorrheic adolescent athletes.
As many as 25% of adolescent and young adult endurance athletes develop amenorrhea, and factors that cause amenorrhea to occur in some, but not all, athletes have not been well characterized. Recent data indicate the critical importance of a negative energy balance state and leptin in regulating the Hypothalamic-pituitary-gonadal (H-P-G) axis. However, these factors do not completely account for alterations in this axis, and other contributing factors are unclear. Our preliminary data indicate the importance of low fat mass and fat related hormones in mediating hypogonadism in young athletes. This study will confirm these data and determine whether low fat mass and altered levels of adipokines, such as leptin and adiponectin, and hormones regulated by fat mass, such as ghrelin and peptide YY (PYY), determine alterations in LH pulsatility. A very concerning impact of amenorrhea in athletes is low bone mineral density (BMD). Preliminary data indicate lower BMD in adolescent athletes with amenorrhea (AA) compared with eumenorrheic athletes (EA) and non-athletic controls. The high prevalence of AA in adolescents is particularly concerning, because this population is potentially at greater risk as it is actively accruing bone. Of importance, bone microarchitecture, a better predictor of bone strength than BMD, has not been studied in AA. Because pubertal increases in estrogen are integral to optimizing peak bone mass, and AA is characterized by hypoestrogenism, this randomized study of transdermal estrogen versus oral estrogen or no estrogen will also examine whether estrogen replacement increases BMD and improves bone microarchitecture in adolescent AA 14-21 years old. EA and sedentary controls will be followed without intervention for this period. Despite the prevalent practice of prescribing oral contraceptives in AA, there is a paucity of data regarding benefits of this intervention in teenagers. Because transdermal estrogen, unlike oral estrogen, does not suppress IGF-1, an important bone anabolic factor, we expect effects of transdermal estrogen to exceed those of oral estrogen or no therapy. In addition, preliminary data indicate that low fat mass and alterations in fat related hormones may contribute to decreased bone accrual rates in athletes, and will be confirmed in this study. To summarize, a better understanding of the pathophysiology of reproductive dysfunction is critical to develop therapeutic strategies that will normalize the reproductive axis and bone accrual, and these are the questions that this study aims to answer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
17Beta-estradiol transdermal patch twice weekly application for 12 months
Drug: Transdermal 17Beta-estradiol, progesterone
One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
Drug: Ethinyl Estradiol + Desogestrel
Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Dietary Supplement: Sham Comparator
Drug pages: EstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ProgesteroneStudies of ProgesteroneProgesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Also known as: Vivelle Dot transdermal patch, Prometrium
Drug pages: Ethinyl EstradiolStudies of Ethinyl EstradiolEthinyl Estradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DesogestrelStudies of DesogestrelDesogestrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
Also known as: Apri
Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Change in Lumbar Bone Mineral Density
Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
Time frame: 12 months
Change in Total Volumetric Bone Mineral Density (Tibia)
Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
Time frame: 12 months
| Milestone | Estrogen Patch | Estrogen Pill | Control |
|---|---|---|---|
| Started | 43 | 40 | 38 |
| Completed | 25 | 22 | 26 |
| Not completed | 18 | 18 | 12 |
| Withdrew: Lost to follow-up | 6 | 11 | 9 |
| Withdrew: Withdrawal by subject | 10 | 7 | 3 |
| Withdrew: Did not start medication | 2 | 0 | 0 |
Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
| g/cm^2 | Estrogen Patch | Estrogen Pill | Control |
|---|---|---|---|
| Change in Lumbar Bone Mineral Density | 0.025 ± 0.011 | 0.008 ± 0.011 | 0.012 ± 0.012 |
Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
| mg HA/cm^3 | Estrogen Patch | Estrogen Pill | Control |
|---|---|---|---|
| Change in Total Volumetric Bone Mineral Density (Tibia) | 7.01 ± 3.06 | 1.17 ± 3.05 | 3.71 ± 4.44 |
Collected over 1 year. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estrogen Patch | 0/43 (0%) | 3/43 (7%) | 10/43 (23.3%) |
| Estrogen Pill | 0/40 (0%) | 0/40 (0%) | 13/40 (32.5%) |
| Control | 0/38 (0%) | 1/38 (2.6%) | 1/38 (2.6%) |
| Event | Estrogen Patch | Estrogen Pill | Control |
|---|---|---|---|
| Fractures or sprainsEndocrine disorders | 3/43 | 0/40 | 0/38 |
| Sinus surgeryRespiratory, thoracic and mediastinal disorders | 0/43 | 0/40 | 1/38 |
| Event | Estrogen Patch | Estrogen Pill | Control |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/43 | 2/40 | 0/38 |
| Vasovagal responseVascular disorders | 0/43 | 2/40 | 0/38 |
| HeadacheNervous system disorders | 2/43 | 1/40 | 0/38 |
| BloatingGeneral disorders | 2/43 | 0/40 | 0/38 |
| Upper respiratory symptomsRespiratory, thoracic and mediastinal disorders | 0/43 | 0/40 | 1/38 |
| FatigueGeneral disorders | 0/43 | 1/40 | 0/38 |
| Breast tendernessEndocrine disorders | 1/43 | 1/40 | 0/38 |
| Fluid retentionMetabolism and nutrition disorders | 0/43 | 1/40 | 0/38 |
| Early mensesEndocrine disorders | 0/43 | 1/40 | 0/38 |
| Yeast infectionInfections and infestations | 0/43 | 1/40 | 0/38 |
Athletes with amenorrhea
| Age, Continuous(years) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| Mean | 19.86 ± 0.40 | 20.30 ± 0.44 | 19.35 ± 0.38 | 19.84 ± 0.41 |
| Sex: Female, Male(Participants) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| Female | 43 | 40 | 38 | 121 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 43 | 40 | 36 | 119 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 4 | 0 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 37 | 38 | 35 | 110 |
| More than one race | 1 | 2 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| United States | 43 | 40 | 38 | 121 |
| BMI(kg/m^2) | Estrogen Patch | Estrogen Pill | Control | Total |
|---|---|---|---|---|
| Mean | 20.45 ± 0.35 | 20.80 ± 0.39 | 20.75 ± 0.34 | 20.67 ± 0.36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2009 to primary completion in Feb 2020, 129 months.
Results were first posted in Mar 2020, 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Progesterone
Massachusetts General Hospital →